Kezar Life Sciences Stock Performance
| KZR Stock | USD 0.82 0.07 7.87% |
On a scale of 0 to 100, Kezar Life holds a performance score of 7. The company secures a Beta (Market Risk) of 1.13, which conveys a somewhat significant risk relative to the market. Kezar Life returns are very sensitive to returns on the market. As the market goes up or down, Kezar Life is expected to follow. Please check Kezar Life's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Kezar Life's current price movements will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Kezar Life Sciences are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady basic indicators, Kezar Life reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug | 08/14/2024 |
2 | De Grey makes moves at Ashburton | 08/15/2024 |
3 | KZR Stock Earnings Kezar Life Sciences Beats EPS for Q2 2024 - MSN | 08/19/2024 |
4 | Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/04/2024 |
5 | JonesTrading Downgrades Kezar Life Sciences - MSN | 09/19/2024 |
6 | Kalamazoo closes in on 33m Pilbara gold project sale | 09/30/2024 |
7 | Kezar zetomipzomib IND for lupus placed on FDA clinical hold | 10/04/2024 |
8 | FDA Put Brakes On Penny Stock Kezar Life Sciences Mid-Stage Study For Lead Development Candidate After Patient Deaths | 10/07/2024 |
9 | Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal | 10/10/2024 |
10 | Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At 1.10Share, Shelves Mid-Stage Lupus Nephritis Study | 10/17/2024 |
| Begin Period Cash Flow | 40.5 M |
Kezar |
Kezar Life Relative Risk vs. Return Landscape
If you would invest 63.00 in Kezar Life Sciences on July 21, 2024 and sell it today you would earn a total of 19.00 from holding Kezar Life Sciences or generate 30.16% return on investment over 90 days. Kezar Life Sciences is generating 0.5762% of daily returns assuming volatility of 6.391% on return distribution over 90 days investment horizon. In other words, 56% of stocks are less volatile than Kezar, and above 89% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Kezar Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kezar Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kezar Life Sciences, and traders can use it to determine the average amount a Kezar Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0902
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KZR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.39 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Kezar Life is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kezar Life by adding it to a well-diversified portfolio.
Kezar Life Fundamentals Growth
Kezar Stock prices reflect investors' perceptions of the future prospects and financial health of Kezar Life, and Kezar Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kezar Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (14.22) % | ||||
| Current Valuation | (87.03 M) | ||||
| Shares Outstanding | 72.96 M | ||||
| Price To Earning | (9.34) X | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 8.59 X | ||||
| Revenue | 7 M | ||||
| EBITDA | (104.17 M) | ||||
| Net Income | (101.87 M) | ||||
| Cash And Equivalents | 306.84 M | ||||
| Cash Per Share | 4.49 X | ||||
| Total Debt | 18.93 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 39.64 X | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (81.64 M) | ||||
| Earnings Per Share | (1.35) X | ||||
| Market Capitalization | 60.11 M | ||||
| Total Asset | 221.24 M | ||||
| Retained Earnings | (350.76 M) | ||||
| Working Capital | 189.21 M | ||||
| Current Asset | 74.47 M | ||||
| Current Liabilities | 2.18 M | ||||
About Kezar Life Performance
Assessing Kezar Life's fundamental ratios provides investors with valuable insights into Kezar Life's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Kezar Life is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 543.87 | 377.62 | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.54) | (0.52) |
Things to note about Kezar Life Sciences performance evaluation
Checking the ongoing alerts about Kezar Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kezar Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kezar Life Sciences is way too risky over 90 days horizon | |
| Kezar Life Sciences has some characteristics of a very speculative penny stock | |
| Kezar Life Sciences appears to be risky and price may revert if volatility continues | |
| Kezar Life Sciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 7 M. Reported Net Loss for the year was (101.87 M) with profit before taxes, overhead, and interest of 0. | |
| Kezar Life Sciences has about 306.84 M in cash with (81.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kezar Life Sciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At 1.10Share, Shelves Mid-Stage Lupus Nephritis Study |
- Analyzing Kezar Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kezar Life's stock is overvalued or undervalued compared to its peers.
- Examining Kezar Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kezar Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kezar Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kezar Life's stock. These opinions can provide insight into Kezar Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.